SF5046

Purpose

• Reassign regulatory responsibilities for health maintenance organizations (HMOs) and county-based purchasers from the Department of Health to the Commissioner of Commerce; provide funding to support the transfer; and adjust related state appropriations and statutory references accordingly. The bill also makes broad updates to nondepository lending rules, virtual currency activity oversight, and several related financial provisions.

Key Provisions by Article

• Article 1: Health plan regulation and funding

  • Appropriates funds (general fund) to the Commissioner of Commerce for regulating HMOs and county-based purchasers.
  • Requires reductions to the Department of Health’s budget (general fund and state government special revenue) to account for transferring regulatory responsibilities to Commerce; these reductions are ongoing.
  • Transfers duties and employees related to health plan regulation from Health to Commerce as part of the realignment.

• Article 2: Prescription Drug Affordability Advisory Council

  • Updates conflict-of-interest rules for the board and advisory council members, including disclosure and mandatory recusal when conflicts exist.
  • Establishes criteria for the board, advisory council, and health officials to identify prescription drug products with affordability challenges. Criteria include:
  • Brand-name drugs or biologics with wholesale acquisition cost (WAC) increases exceeding 15% or more than $3,000 in a 12-month window (adjusted for CPI).
  • Brand-name drugs/biologics with a WAC of $60,000 or more per year or per course of treatment.
  • Biosimilars not at least 20% cheaper than the referenced biologic at introduction.
  • Generics with a WAC of $100 or more per 30-day supply, course of treatment, or unit, after CPI adjustments (with specified sub-criteria).
  • Allows the board, in consultation with the advisory council and the health department, to identify other drugs posing significant affordability challenges (including those relevant to public health emergencies).
  • Requires public disclosure of identified drug names and price information, with exemptions for proprietary data or data protected as trade secrets or not public data.
  • Repeals certain existing statutes (62J.86(2) and 62J.88).

• Article 3: Nondepository institutions and related financial provisions

  • Expands the regulatory role of the Commissioner of Commerce over a wide range of financial institutions and lending activities, including banks, savings institutions, trust companies, mortgage originators/servicers, and other federally or state-regulated lenders.
  • Includes authority related to loans and loan guarantees, mortgage purchases and servicing, and related credit activities, with alignment to programs administered by federal agencies (HUD, VA, Farmers Home Administration, Fannie Mae, Freddie Mac) and other federal entities.
  • Revisions to definitions and terminology for consumer loans, APR, finance charges, credit cards, credit sales, and related terms to support updated regulation.
  • Updates to the treatment of virtual currency activities:
  • Adds virtual currency business activities to license requirements.
  • Establishes recordkeeping and reporting requirements (five-year records, detailed transaction data, aggregate transaction data, general ledger, bank records, disputes, and uncompleted transactions).
  • Mandates record formats that allow the state to assess compliance with the chapter and applicable law.
  • Provides licensing and regulatory structure changes, including posting requirements for licenses and clarifications on exemptions for certain government-related entities or federally regulated mortgage insurers/purchasers.
  • Revisions to existing licensing and posting requirements, including a specific requirement to display license numbers on internet pages when serving customers online.
  • Clarifies how some mortgage-related activities can proceed under other statutes (e.g., using 47.59 for certain credit sales by third parties), while retaining applicable provisions across the board.

Significant Changes to Law

• Transfer of health plan regulation from the Department of Health to the Commissioner of Commerce, with corresponding budget adjustments.
• New or expanded authority for Commerce to regulate HMOs, county-based purchasers, and certain lending activities previously overseen by other agencies.
• Reforms to conflict-of-interest rules and drug-price transparency for the Prescription Drug Affordability framework, including public disclosure of price information for identified drugs.
• Introduction of comprehensive virtual currency regulatory requirements for licensees, including extensive recordkeeping, reporting, and auditability obligations.
• Revisions to licensing requirements and definitions for consumer loans, small loans, and related credit products, aligning various subsections under Commerce’s regulatory umbrella.
• Repeal of some existing provisions (e.g., certain sections of the prescription drug affordability statutes) as part of the modernization and consolidation of authorities.

Fiscal and Administrative Implications

• A new ongoing general fund appropriation of 1.75 million for Commerce to regulate HMOs and county-based purchasers, with corresponding ongoing reductions to Health’s budget:
  • 1.75 million to Health’s general fund (to be redirected to Commerce).
  • 1.836 million to Health’s state government special revenue (to be redirected to Commerce).
• Transfers of duties, staff, and responsibilities related to health plan regulation, as well as related reporting requirements.

Public Access and Data Considerations

• Drug price information identified under the Prescription Drug Affordability provisions is generally to be made public, with careful handling of proprietary and trade-secret data.
• Certain government- or federally regulated entities may be exempt or treated differently for licensing and regulatory purposes.

Administrative Details

• The bill involves modifications to multiple Minnesota Statutes (e.g., sections 47.20, 47.59, 47.60, 53.04, 53B.74, 53C.09, 56.002, 56.01, 56.05) and adds new subdivisions to address contemporary financial activities, including virtual currency operations.
• Requires ongoing reporting and recordkeeping to support regulatory oversight, including five-year transaction histories for virtual currency activities and public disclosure of identified affordability-challenged drugs.

Potential Impacts

• Health plan consumers and purchasers could see a shift in regulatory oversight and potential changes in how health plans are regulated and monitored.
• Financial services providers, especially nondepository lenders and virtual currency businesses, will face expanded state licensing, reporting, and recordkeeping requirements.
• Drug affordability transparency could influence pricing discussions and public awareness of high-cost drugs.

Public Engagement and Oversight

• New disclosures and transparency measures are designed to inform the public about drug price dynamics and identified affordability challenges, while balancing protections for sensitive data.

Relevant Terms - Health maintenance organization (HMO) - County-based purchaser - Commissioner of Commerce - Department of Health - Prescription Drug Affordability Advisory Council - Conflict of interest - Recusal - Wholesale Acquisition Cost (WAC) - Brand-name drugs - Biosimilars - Generics - Public data / trade secret / proprietary information - Nondepository institutions - Banks, savings banks, trust companies - Mortgage originators and servicers - Fannie Mae (FNMA) / Freddie Mac (FHLMC) - Virtual currency / virtual currency business activities - Tangible net worth - NMLS (Nationwide Multistate Licensing System) - Licensing and posting requirements - Consumer small loans - APR / finance charge - Credit sale / credit card - Public disclosure of drug prices and related information